A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect.

Provide are beneficial bacteria that can be beneficially applied across a wide range of age groups and a composition containing the same. Bifidobacterium longum subspecies longum NITE BP-02568 and/or Bifidobacterium longum subspecies longum NITE BP-02569; and Bifidobacterium longum subspecies longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

Provide are beneficial bacteria that can be beneficially applied across a wide range of age groups and a composition containing the same. Bifidobacterium longum subspecies longum NITE BP-02568 and/or Bifidobacterium longum subspecies longum NITE BP-02569; and Bifidobacterium longum subspecies longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

Disclosed herein is disclosed is a nutritional food product (supplement) comprising creatine, which may be provided in a gummy form. In certain embodiments, the supplement may comprise about 6% to 35% by weight of creatine. In some embodiments, the supplement may comprise a gelling agent, a sweetener, and water.

Disclosed herein is disclosed is a nutritional food product (supplement) comprising creatine, which may be provided in a gummy form. In certain embodiments, the supplement may comprise about 6% to 35% by weight of creatine. In some embodiments, the supplement may comprise a gelling agent, a sweetener, and water.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

An infant formula for use in preventing or reducing the occurrence of allergic sensitisation in an infant, wherein the infant formula comprises 0.8-2.5 g/L 2′-fucosyllactose (2′FL) and/or 0.05-0.2 g/L lacto-N-neotetraose (LNnT).

An infant formula for use in preventing or reducing the occurrence of allergic sensitisation in an infant, wherein the infant formula comprises 0.8-2.5 g/L 2′-fucosyllactose (2′FL) and/or 0.05-0.2 g/L lacto-N-neotetraose (LNnT).